{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1116.222","meta":{"versionId":"9","lastUpdated":"2021-03-06T01:00:18.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222","version":"20210306","name":"Aprepitant Oral","status":"active","date":"2021-03-06T01:00:18-05:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","concept":[{"code":"1729308","display":"aprepitant 125 MG Powder for Oral Suspension"},{"code":"403810","display":"aprepitant 80 MG Oral Capsule"},{"code":"403811","display":"aprepitant 125 MG Oral Capsule"},{"code":"644088","display":"aprepitant 40 MG Oral Capsule"},{"code":"754508","display":"{1 (aprepitant 125 MG Oral Capsule) / 2 (aprepitant 80 MG Oral Capsule) } Pack"}]}]},"expansion":{"identifier":"urn:uuid:108627a2-952b-4927-9e84-97ff470c4b5d","timestamp":"2022-06-10T04:46:00-04:00","total":5,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"1729308","display":"aprepitant 125 MG Powder for Oral Suspension"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"403810","display":"aprepitant 80 MG Oral Capsule"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"403811","display":"aprepitant 125 MG Oral Capsule"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"644088","display":"aprepitant 40 MG Oral Capsule"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"05022022","code":"754508","display":"{1 (aprepitant 125 MG Oral Capsule) / 2 (aprepitant 80 MG Oral Capsule) } Pack"}]}}